2. Lipids
  3. Sterol Lipids
  4. Bile Acids

Bile Acids

Bile Acids (151):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19696
    Tauroursodeoxycholate 14605-22-2 99.93%
    Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an orally active endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.
    Tauroursodeoxycholate
  • HY-B0172
    Lithocholic acid 434-13-9 99.96%
    Lithocholic acid is a toxic secondary bile acid that can promote intrahepatic cholestasis and promote tumorigenesis. Lithocholic acid is also a FXR antagonist and a PXR/SXR agonist.
    Lithocholic acid
  • HY-76847
    Chenodeoxycholic Acid 474-25-9 99.93%
    Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.
    Chenodeoxycholic Acid
  • HY-N0593
    Deoxycholic acid 83-44-3 99.95%
    Deoxycholic acid (cholanoic acid), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5.
    Deoxycholic acid
  • HY-13771
    Ursodeoxycholic acid 128-13-2 99.94%
    Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active.
    Ursodeoxycholic acid
  • HY-W740611
    Trihydroxycoprostane 547-96-6
    Trihydroxycoprostane (THCP) is a polyhydroxysterane compound with a 5β configuration. ITrihydroxycoprostane acts as a key intermediate in the biosynthesis of bile acids from cholesterol and also serves as an important sterol metabolite generated by host-gut microbiota interactions. Trihydroxycoprostane can be used for mechanistic studies of diseases such as non-alcoholic fatty liver disease, inflammatory bowel disease, and bile acid metabolism disorders.
    Trihydroxycoprostane
  • HY-134837
    (3α,5β,7α,25R)-3,7-Dihydroxycholestan-26-oic acid 23740-16-1
    (3α,5β,7α,25R)-3,7-Dihydroxycholestan-26-oic acid (compound (25S)-3α,7α-dihydroxy-5β-cholestanoyl-CoA) is a Ursodeoxycholic Acid (HY-13771) precursor. (3α,5β,7α,25R)-3,7-Dihydroxycholestan-26-oic acid is a key intermediary metabolite in the pathway of bile acid biosynthesis.
    (3α,5β,7α,25R)-3,7-Dihydroxycholestan-26-oic acid
  • HY-B1788
    Taurocholic acid 81-24-3 99.83%
    Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect.
    Taurocholic acid
  • HY-N0324
    Cholic acid 81-25-4 99.80%
    Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active.
    Cholic acid
  • HY-N2027
    Taurochenodeoxycholic acid 516-35-8 99.90%
    Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties.
    Taurochenodeoxycholic acid
  • HY-N2334
    Glycochenodeoxycholic acid 640-79-9 99.84%
    Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC).
    Glycochenodeoxycholic acid
  • HY-19696A
    Tauroursodeoxycholate sodium 35807-85-3 98.40%
    Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.
    Tauroursodeoxycholate sodium
  • HY-N1423
    Glycocholic acid 475-31-0 99.90%
    Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
    Glycocholic acid
  • HY-N0593A
    Deoxycholic acid sodium salt 302-95-4 99.89%
    Deoxycholic acid sodium salt (sodium deoxycholate), a bile acid, is a by-product of intestinal metabolism, that activates the G protein-coupled bile acid receptorTGR5.
    Deoxycholic acid sodium salt
  • HY-N0545
    Taurocholic acid sodium 145-42-6 99.82%
    Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect.
    Taurocholic acid sodium
  • HY-125731
    Glycodeoxycholic acid 360-65-6 99.91%
    Glycodeoxycholic Acid is a natural product found in Streptomyces nigricans, Trypanosoma brucei and C. elegans. Glycodeoxycholic Acid induces hepatocyte necrosis and autophagy in patients with obstructive cholestasis.
    Glycodeoxycholic acid
  • HY-113962
    7α,25-Dihydroxycholesterol 64907-22-8 99.88%
    7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells.
    7α,25-Dihydroxycholesterol
  • HY-N1424
    Glycoursodeoxycholic acid 64480-66-6 99.80%
    Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid.
    Glycoursodeoxycholic acid
  • HY-N0169
    Hyodeoxycholic acid 83-49-8 99.94%
    Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells.
    Hyodeoxycholic acid
  • HY-125801
    3-Oxo-5β-cholanoic acid 1553-56-6 99.37%
    3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM).
    3-Oxo-5β-cholanoic acid